Search Results - "Kuusisto, Milla E.L."

Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia by Kuusanmäki, Heikki, Kytölä, Sari, Vänttinen, Ida, Ruokoranta, Tanja, Ranta, Amanda, Huuhtanen, Jani, Suvela, Minna, Parsons, Alun, Holopainen, Annasofia, Partanen, Anu, Kuusisto, Milla E L, Koskela, Sirpa, Räty, Riikka, Itälä-Remes, Maija, Västrik, Imre, Dufva, Olli, Siitonen, Sanna, Porkka, Kimmo, Wennerberg, Krister, Heckman, Caroline A, Ettala, Pia, Pyörälä, Marja, Rimpiläinen, Johanna, Siitonen, Timo, Kontro, Mika

“…The BCL-2 inhibitor venetoclax has revolutionized the treatment of acute myeloid leukemia (AML) in patients not benefiting from intensive chemotherapy…”
Get full text

Progression-free survival after front line, second line and third line in patients with follicular lymphoma treated in clinical practice by Rajamaki, Aino, Sorigue, Marc, Prusila, Roosa E I, Kuusisto, Milla E L, Kuitunen, Hanne, Jantunen, Esa, Mercadal, Santiago, Turpeenniemi-Hujanen, Taina, Sancho, Juan-Manuel, Sunela, Kaisa, Kuittinen, Outi

“…The modern-day therapeutic landscape for follicular lymphoma (FL) includes a number of highly effective therapies. We set out to determine progression-free…”
Get full text

P562: CAPILLARY BLOOD SAMPLING ALLOWS FEASIBLE METHOD FOR VENETOCLAX CONCENTRATION MEASUREMENT IN AN ACADEMIC MULTICENTER CLINICAL TRIAL CONTEXT by Kytölä, Sari, Vänttinen, Ida, Kuusanmäki, Heikki, Ruokoranta, Tanja, Kurkela, Mika, Kiiski, Johanna, Holopainen, Annasofia, Partanen, Anu, Kuusisto, Milla E.L., Koskela, Sirpa, Räty, Riikka, Itälä‐Remes, Maija, Ettala, Pia, Rimpiläinen, Johanna, Siitonen, Timo, Pyörälä, Marja, T. Backman, Janne, Niemi, Mikko, Kontro, Mika

Get full text

Chemokine Profile Is Different in Normal Testis Compared to Seminoma - Especially in Tumor Infiltrating Lymphocytes by Händelin, Jonas M, Teppo, Hanna-Riikka, Haapasaari, Kirsi-Maria, Ollikainen, Riina K, Kemppainen, Janette, Kuitunen, Hanne, Kuittinen, Outi, Kuusisto, Milla E L

“…Testicular cancers, particularly seminomas and non-seminomas, generally have a favorable prognosis, although a small subset of patients experience mortality…”
Get more information

Ex Vivo Venetoclax Sensitivity Predicts Clinical Response in Acute Myeloid Leukemia in the Prospective VenEx Trial by Kytölä, Sari, Vänttinen, Ida Maria, Ruokoranta, Tanja, Partanen, Anu, Holopainen, Annasofia, Saad, Joseph, Kuusisto, Milla E L, Koskela, Sirpa, Räty, Riikka Katariina, Itälä-Remes, Maija, Västrik, Imre, Suvela, Minna, Parsons, Alun Owen, Porkka, Kimmo, Wennerberg, Krister, Heckman, Caroline A, Jalkanen, Tero, Huttunen, Teppo, Ettala, MD, Pia, Rimpiläinen, Johanna, Siitonen, Timo, Pyörälä, Marja, Kuusanmäki, Heikki, Kontro, Mika

“…The BCL2 inhibitor venetoclax has shown promise for treating acute myeloid leukemia (AML). However, identifying patients likely to respond remains a challenge,…”
Get full text

R‐bendamustine in the treatment of nodular lymphocyte predominant Hodgkin lymphoma—An extended follow‐up by Vuolio, Tero, Kuittinen, Outi, Väyrynen, Juha P., Teppo, Hanna‐Riikka, Prusila, Roosa E. I., Rämet, Maria, Kuitunen, Hanne, Paloneva, Timo, Kuusisto, Milla E. L.

Get full text

Ex Vivo Drug Sensitivity Testing to Predict Response to Venetoclax + Azacitidine in Acute Myeloid Leukemia: Interim Results of the Prospective Multicenter Phase II Venex Trial by Kuusanmäki, Heikki, Kytölä, Sari, Vänttinen, Ida, Ranta, Amanda, Ruokoranta, Tanja, Holopainen, Annasofia, Koskela, Sirpa, Kuusisto, Milla E.L., Porkka, Kimmo, Räty, Riikka, Västrik, Imre, Wennerberg, Krister, Heckman, Caroline A., Ettala, Pia, Pyörälä, Marja, Rimpiläinen, Johanna, Siitonen, Timo, Kontro, Mika

“…Background BCL-2 inhibitor venetoclax (Ven) in combination with azacitidine (Aza) has substantially improved overall response rates (ORR) and overall survival…”
Get full text

Mortality among patients with low‐grade follicular lymphoma: A binational retrospective analysis by Rajamäki, Aino, Hujo, Mika, Sund, Reijo, Prusila, Roosa E. I., Kuusisto, Milla E. L., Kuitunen, Hanne, Jantunen, Esa, Mercadal, Santiago, Sorigue, Marc, Sancho, Juan‐Manuel, Sunela, Kaisa, Kuittinen, Outi

“…Background The life expectancy of patients with follicular lymphoma (FL) has improved considerably since the introduction of rituximab. This study examined the…”
Get full text

Link between disease status at 24 months and mortality in follicular lymphoma by Rajamäki, Aino, Hujo, Mika, Sund, Reijo, Prusila, Roosa E. I., Kuusisto, Milla E. L., Kuitunen, Hanne, Jantunen, Esa, Mercadal, Santiago, Sorigue, Marc, Sancho, Juan‐Manuel, Kuittinen, Outi, Sunela, Kaisa

Get full text

Ex Vivo Venetoclax Sensitivity Testing Predicts Response and Overall Survival in De Novo and s/R/R AML Patients Treated with Azacitidine and Venetoclax by Kytölä, Sari, Vänttinen, Ida, Ruokoranta, Tanja, Holopainen, Annasofia, Partanen, Anu, Kuusisto, Milla E.L., Koskela, Sirpa, Räty, Riikka, Itälä-Remes, Maija, Ranta, Amanda, Suvela, Minna, Parsons, Alun, Västrik, Imre, Siitonen, Sanna M., Porkka, Kimmo, Wennerberg, Krister, Heckman, Caroline A., Ettala, Pia, Rimpiläinen, Johanna, Siitonen, Timo, Pyörälä, Marja, Kuusanmäki, Heikki, Kontro, Mika

Get full text

Incidence and clinicopathological features of Follicular T-cell lymphoma in Finland: a population-based immunohistochemical study by Kiiskilä, Jenni, Uotila, Pyry, Haapasaari, Kirsi-Maria, Kauppila, Saila, Teppo, Hanna-Riikka, Kuusisto, Milla E.L., Lemma, Siria, Turpeenniemi-Hujanen, Taina, Vornanen, Martine, Eray, Mine, Kuittinen, Outi

“…Follicular T-cell lymphoma (FTCL) is a rare subtype of mature T-cell lymphoma. It was recently recognized as a separate lymphoma entity in the 2017 revised…”
Get full text

Different chemokine profile between systemic and testicular diffuse large B-cell lymphoma by Ollikainen, Riina K., Kotkaranta, Pyry H., Kemppainen, Janette, Teppo, Hanna-Riikka, Kuitunen, Hanne, Pirinen, Risto, Turpeenniemi-Hujanen, Taina, Kuittinen, Outi, Kuusisto, Milla E.L.

“…Although treatment for diffuse large B-cell lymphoma (DLBCL) has taken some notable steps in the 2000s, there are still subgroups of patients suffering from…”
Get full text

Female patients with follicular lymphoma have a better prognosis if primary remission lasts over 24 months by Rajamäki, Aino, Sunela, Kaisa, Prusila, Roosa E. I., Kuusisto, Milla E. L., Mercadal, Santiago, Selander, Tuomas, Kuitunen, Hanne, Pollari, Marjukka, Jantunen, Esa, Nystrand, Ilja, Sancho, Juan-Manuel, Sorigue, Marc, Kuittinen, Outi

“…Findings regarding the role of sex in follicular lymphoma (FL) are contradictory and the prognostic value of sex among patients with early progression of…”
Get full text

Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era by Prusila, Roosa E. I., Sorigue, Marc, Jauhiainen, Jyrki, Mercadal, Santiago, Postila, Aleksi, Salmi, Petteri, Tanhua, Taru, Tikkanen, Susanna, Kakko, Sakari, Kuitunen, Hanne, Pollari, Marjukka, Nystrand, Ilja, Kuusisto, Milla E. L., Vasala, Kaija, Jantunen, Esa, Korkeila, Eija, Karihtala, Peeter, Sancho, Juan‐Manuel, Turpeenniemi‐Hujanen, Taina, Kuittinen, Outi

“…Summary Follicular lymphoma (FL) is the most common indolent lymphoma. Currently there are many comparable treatment options available for FL. When selecting…”
Get full text

The Transcription Factor Twist1 Has a Significant Role in Mycosis Fungoides (MF) Cell Biology: An RNA Sequencing Study of 40 MF Cases by Häyrinen, Marjaana J, Kiiskilä, Jenni, Ranki, Annamari, Väkevä, Liisa, Barton, Henry J, Kuusisto, Milla E L, Porvari, Katja, Kuitunen, Hanne, Haapasaari, Kirsi-Maria, Teppo, Hanna-Riikka, Kuittinen, Outi

“…The purpose of this RNA sequencing study was to investigate the biological mechanism underlying how the transcription factors (TFs) Twist1 and Zeb1 influence…”
Get full text

Drug‐induced pneumonitis risk in diffuse large B‐cell/follicular lymphoma patients treated with R‐CHOP‐like regimen is associated with the use of granulocyte colony‐stimulating growth factors by Kaprio, Elina, Prusila, Roosa, Tokola, Susanna, Kuusisto, Milla E. L., Jantunen, Esa, Kuitunen, Hanne, Turpeenniemi‐Hujanen, Taina, Kuittinen, Outi

“…Background Rituximab‐based combinations are the standard of care in diffuse large B‐cell lymphoma (DLBCL) and follicular lymphoma (FL). Despite being on market…”
Get full text

Incidence of solid cancer in patients with follicular lymphoma by Sorigue, Marc, Prusila, Roosa E I, Jauhiainen, Jyrki, Mercadal, Santiago, Postila, Aleksi, Salmi, Petteri, Tanhua, Taru, Tikkanen, Susanna, Kakko, Sakari, Kuitunen, Hanne, Pollari, Marjukka, Nystrand, Ilja, Kuusisto, Milla E L, Vasala, Kaija, Jantunen, Esa, Korkeila, Eija, Karihtala, Peeter, Sancho, Juan-Manuel, Turpeenniemi-Hujanen, Taina, Kuittinen, Outi

“…Patients with follicular lymphoma (FL) have classically had a higher risk of solid cancers than the general population, but there is little data available in…”
Get more information

Testis-Specific Thioredoxins TXNDC2, TXNDC3, and TXNDC6 Are Expressed in Both Testicular and Systemic DLBCL and Correlate with Clinical Disease Presentation by Chan, Mikko C., Savela, Janette, Ollikainen, Riina K., Teppo, Hanna-Riikka, Miinalainen, Ilkka, Pirinen, Risto, Kari, Esa J. M., Kuitunen, Hanne, Turpeenniemi-Hujanen, Taina, Kuittinen, Outi, Kuusisto, Milla E. L.

“…DLBCL is the most common type of non-Hodgkin lymphoma with a substantial group of patients suffering a poor prognosis. Therefore more specific markers are…”
Get full text

Estimating the Lifetime Treatment Burden of Patients With Follicular Lymphoma: A Retrospective Study Using Real-World Multicenter Data by Rajamäki, Aino, Hujo, Mika, Sund, Reijo, Prusila, Roosa E I, Kuusisto, Milla E L, Kuitunen, Hanne, Jantunen, Esa, Mercadal, Santiago, Sorigue, Marc, Sancho, Juan-Manuel, Sunela, Kaisa, Kuittinen, Outi

“…Although follicular lymphoma is characterized by long natural history and frequent relapses, data on the number of patients receiving subsequent therapy lines…”
Get more information